BRAF and colorectal carcinoma: Drawing from this evidence, one phase I/II and one phase II clinical trials are currently investigating the activity and efficacy of BRAF + MEK + PD-1 inhibitors in stage III and IV CRC patients harboring an activating BRAF mutation (NCT04044430 and NCT03668431) [55,56].